TG Therapeutics, Inc. TGTX

The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling.

TG Therapeutics (TGTX) steps into the spotlight ahead of its H.C. Wainwright conference appearance on September 14, drawing fresh attention after the stock recently bounced off its 50-day moving average. Across the past few months, TG Therapeutics has leaned into stronger momentum, with a 30-day share price return of 12.36% and a year-to-date share price return of 92.86%. The one-year total shareholder return of 73.17% and roughly 5x three-year total shareholder return suggest earlier buyers...

A positive day two reaction to the Fed rate hike and hawkish Warsh comments? AMD, Bloom Energy are flirting with buy signals.

TG Therapeutics stock showed technical strength Wednesday, bounding off its 50-day moving average and nearing a breakout on the weekly chart.

Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ETNEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 28th Annual Global Investment Conference, being held on September 14 - 16, 2026. The fireside chat is scheduled to take place on Monday, September 14, 2026, at 12:00pm ET. A live webcast of the fireside chat will be av

Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Fireside chat scheduled for Wednesday, September 9, 2026, at 11:30am ETNEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare Conference, being held on September 9 - 11, 2026. The fireside chat is scheduled to take place on Wednesday, September 9, 2026, at 11:30am ET. A live webcast of the fireside chat will be available on the Eve

TG Therapeutics is Wednesday's IBD Stock Of The Day. Shares of the multiple sclerosis biotech has topped an early entry and is near a breakout.

TGTX shares opened lower on Tuesday after Novartis said its drug remibrutinib improved multiple sclerosis in late-stage trials.

Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average.

The mergers and acquisitions-focused blog Betaville published an alert on Friday signaling fresh interest from an unnamed suitor for TG Therapeutics, Seeking Alpha reported.

TG Therapeutics stock rips higher on takeover speculation. But should you chase the momentum on Friday? Let’s find out!

TG Therapeutics (TGTX) drew fresh attention after reporting second quarter 2026 results, with revenue of US$240.34 million and earnings of US$0.05 per share, alongside higher full-year revenue guidance near US$950 million. See our latest analysis for TG Therapeutics. Despite raising guidance and reporting strong revenue growth for BRIUMVI, TG Therapeutics has seen its recent momentum cool, with the share price down 11.26% over 1 day and 15.86% over 7 days. However, the year-to-date share...